An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL / SLL)
18 Years and older, Male and Female
This study will enroll subjects with previously untreated CLL / SLL into two cohorts (Cohort 1 without del[17p] and Cohort 2 with del[17p]). Cohort 1 subjects will receive either "BGB-3111 alone" or "bendamustine (B) and rituximab (R)". Cohort 2 subjects will receive BGB-3111 alone. The primary purpose is to evaluate the efficacy and safety of BGB-3111 versus bendamustine and rituximab in Cohort 1.
This is a global phase 3, open label, randomized study of BGB-3111 versus bendamustine plus
rituximab (B+R) in subjects with previously untreated chronic lymphocytic leukemia or small
lymphocytic lymphoma (CLL/SLL), including subjects without del(17p) [Cohort 1] and subjects
with del(17p) [Cohort 2]. Subjects in Cohort 1 are randomized 1:1 to BGB-3111 (Arm A) or
bendamustine plus rituximab (Arm B). Randomization will be stratified by age, Binet stage,
immunoglobulin variable region heavy chain (IGHV) mutational status, and geographic region.
Subjects in Cohort 2 receive treatment with BGB-3111.
Treatment Sites in Georgia
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials